Celgene Reports Third Quarter 2018 Operating and Financial Results

— Total net product sales of $3,890 million, increased 18% Y/Y — Raising full-year total revenue guidance to ~$15.2 billion and OTEZLA ® net product sales to ~$1.6 billion — Showcasing our next-generation pipeline across multiple disease areas at ASH — Appointed Dr. Alise Reicin as President of Global Clinical Development